Excitotoxicity mediated by glutamate receptors plays crucial roles in ischemia and other neurodegenerative diseases. Whereas overactivation of ionotropic glutamate receptors is neurotoxic, the role of metabotropic glutamate receptors (mGluRs), and especially mGluR1, remains equivocal. Here we report that activation of NMDA receptors results in calpain-mediated truncation of the C-terminal domain of mGluR1a at Ser 936 . The truncated mGluR1a maintains its ability to increase cytosolic calcium while it no longer activates the neuroprotective PI 3 K-Akt signaling pathways. Full-length and truncated forms of mGluR1a play distinct roles in excitotoxic neuronal degeneration in cultured neurons. A fusion peptide derived from the calpain cleavage site of mGluR1a efficiently blocks NMDA-induced truncation of mGluR1a in primary neuronal cultures and exhibits neuroprotection against excitotoxicity both in vitro and in vivo. These findings shed light on the relationship between NMDA and mGluR1a and indicate the existence of a positive feedback regulation in excitotoxicity involving calpain and mGluR1a.
SUMMARY
Excitotoxicity mediated by glutamate receptors plays crucial roles in ischemia and other neurodegenerative diseases. Whereas overactivation of ionotropic glutamate receptors is neurotoxic, the role of metabotropic glutamate receptors (mGluRs), and especially mGluR1, remains equivocal. Here we report that activation of NMDA receptors results in calpain-mediated truncation of the C-terminal domain of mGluR1a at Ser
936
. The truncated mGluR1a maintains its ability to increase cytosolic calcium while it no longer activates the neuroprotective PI 3 K-Akt signaling pathways. Full-length and truncated forms of mGluR1a play distinct roles in excitotoxic neuronal degeneration in cultured neurons. A fusion peptide derived from the calpain cleavage site of mGluR1a efficiently blocks NMDA-induced truncation of mGluR1a in primary neuronal cultures and exhibits neuroprotection against excitotoxicity both in vitro and in vivo. These findings shed light on the relationship between NMDA and mGluR1a and indicate the existence of a positive feedback regulation in excitotoxicity involving calpain and mGluR1a.
INTRODUCTION
Glutamate is the major excitatory neurotransmitter in the brain. Receptors for glutamate consist of three types of ionotropic receptors, namely NMDA, AMPA, and kainate receptors, and three groups of metabotropic receptors. In addition to their physiological roles in normal neurotransmission, glutamate receptors play critical roles in neuronal death resulting from ischemia and other neurodegenerative diseases. Ionotropic glutamate receptors, especially NMDA receptors, have been repeatedly shown to contribute to excitotoxicity. However, the roles of metabotropic glutamate receptors, especially of group I metabotropic glutamate receptors (mGluRI, including mGluR1 and mGluR5), in excitotoxicity remain controversial.
Activation of group I mGluRs appears to be neuroprotective under various conditions. The agonist of group I mGluRs, DHPG, prevented nitric oxide-, hydrogen peroxide-, or platelet-activating factor-induced neurotoxicity in neuronal cultures (Vincent and Maiese, 2000; Zhu et al., 2004) . Activation of mGluRs also protected neurons from oxidative stress (Sagara and Schubert, 1998) . In organotypic hippocampal slice cultures, mGluR1 activation protected against NMDA-induced excitotoxicity (Blaabjerg et al., 2003) . Selective mGluRI blockade exacerbated Aß toxicity (Allen et al., 1999) . Recent studies indicated that the neuroprotective effects of mGluRI were mediated by activation of PI 3 K-Akt signaling through the formation of an mGluRI-Homer-PIKE-L signaling complex (Rong et al., 2003) . Activation of Akt and neuroprotection by mGluRI were also reported in other studies (Hou and Klann, 2004; Chong et al., 2006) .
Numerous experiments demonstrate neurotoxic effects of mGluRI activation, however. In models of cerebral ischemia, activation of mGluRI, especially of mGluR1, is neurotoxic, while antagonists of mGluR1 are neuroprotective. The neurotoxic effects of mGluR1 activity in ischemia might be due to their effects on cytosolic free Ca 2+ and their stimulation of glutamate release (PellegriniGiampietro, 2003) .
Because multiple types of glutamate receptors are simultaneously activated under excitotoxic conditions, interactions between receptors might play important roles in determining the outcome of toxic insults. The present study was therefore directed at evaluating interactions between NMDA and mGluR1a receptors. Our results indicate that overactivation of NMDA receptors alters signaling mechanisms and roles in excitotoxicity of mGluR1a through calpain-mediated truncation.
RESULTS

NMDA Receptor Activation Induces C-Terminal Truncation of mGluR1a
To detect possible mGluR1a modifications following glutamate-induced excitotoxicity, cultured cortical neurons (14-18 days in vitro; DIV) were incubated with glutamate (100 mM) for 1-60 min. Total cell lysate was collected immediately after treatment and subjected to SDS-PAGE and immunoblotting with an antibody against the carboxyl terminus (residues 1142-1160) of mGluR1a ( Figure 1A ). Levels of full-length mGluR1a decreased with increasing incubation time, while levels of a low-molecular weight band at about 38 kDa increased, suggesting that truncation of mGluR1a occurred at the C terminus. To probe the amino terminus of mGluR1a after truncation, cortical neurons were transfected with an mGluR1a construct tagged with a myc epitope at the N terminus (mycmGluR1a, the EQKLISEEDL epitope, was inserted inframe after Ala 30 of mGluR1a; Francesconi and Duvoisin, 2002) after 3 days in vitro. Neurons were transfected with a calcium phosphate precipitation method modified for high transfection rate (Jiang et al., 2004) . One week later, transfected neurons were treated with 100 mM glutamate for 1 hr and total lysates were processed for western blots. When probed with an anti-myc antibody, blots revealed a low-molecular weight band at about 100 kDa after glutamate treatment ( Figure 1B) , which corresponds to the N-terminal fragment after truncation. The optical density of the original myc-mGluR1a did not decrease significantly, suggesting that only a small fraction of overexpressed myc-mGluR1a was cleaved. Because the apparent molecular weight of mGluR1a on SDS-PAGE is about 140 kDa, our data suggested that glutamate induced truncation of mGluR1a in the C terminus, most likely at a single cleavage site.
To test for the specificity of glutamate-mediated truncation of mGluR1a, immunoblots were also probed with an antibody against mGluR5, another member of group I mGluRs, which shares a high similarity with mGluR1a. As shown in Figure 1C , levels of mGluR5 were not significantly altered by glutamate. Similarly, no significant changes occurred to the GluR2/3 subunits of AMPA receptors, or to the vesicular glutamate transporter (VGluT1), a presynaptic protein in glutamatergic synapses.
Selective glutamate receptor antagonists were used to identify the glutamate receptor(s) involved in mGluR1a truncation. Glutamate (100 mM, 1 hr) induced a significant reduction in the levels of mGluR1a. An NMDA receptor antagonist, MK-801 (10 mM), completely blocked this effect, whereas the non-NMDA glutamate receptor antagonist, DNQX (100 mM), had no effect. Similarly, mGluR1 blockade with LY367385 (100 mM) or mGluR5 blockade with MPEP (100 mM) did not prevent truncation (Figures 1D and 1F) . Furthermore, when cortical neurons were treated with NMDA (50 mM, 1 hr), a similar degree of mGluR1a truncation was produced ( Figure 1E ). To characterize NMDA-induced mGluR1a truncation, concentration and time dependencies of NMDA effects were studied. Cortical neurons were first incubated with 1-100 mM NMDA for a fixed period of time (1 hr) ( Figure 2G ). The minimum concentration of NMDA required to induce significant mGluR1a truncation was 10 mM (p < 0.001, n = 4, Student's t test for control versus 10 mM). In a following experiment, cortical neurons were incubated with 10 mM NMDA for 1-60 min ( Figure 2H ). The minimum time required for 10 mM NMDA to induce truncation was 5 min (p < 0.01, n = 4, Student's t test for control versus 5 min). In summary, these data indicate that activation of NMDA receptors but not non-NMDA glutamate receptors results in (B) Neurons were transfected with mycmGluR1a and treated with glutamate. Total cell lysates were probed with anti-myc antibody (the schematic shows locations of epitopes; the arrow indicates the putative cleavage site). (C) Neurons were treated with glutamate and whole lysates were blotted with antibodies against mGluR5, GluR2/3, and VGluT1. (D and F) Representative blot and quantification of the effects of an NMDA receptor antagonist on glutamate-induced truncation of mGluR1a. Neurons were treated with glutamate alone (n = 7) or glutamate + MK 801 (n = 4), DNQX (n = 5), LY367385 (n = 4), or MPEP (n = 4). Total cell lysates were blotted with anti-mGluR1a [1142] [1143] [1144] [1145] [1146] [1147] [1148] [1149] [1150] [1151] [1152] [1153] [1154] [1155] [1156] [1157] [1158] [1159] [1160] . (E and F) NMDA induced a similar truncation of mGluR1a. Neurons were treated with glutamate or NMDA (n = 5) and whole lysates were blotted with anti-mGluR1a [1142] [1143] [1144] [1145] [1146] [1147] [1148] [1149] [1150] [1151] [1152] [1153] [1154] [1155] [1156] [1157] [1158] [1159] [1160] . Results are means ± SEM. *p < 0.001, Student's t test. (G and H) Concentration and time dependency of NMDA-induced truncation of mGluR1a. Cortical neurons were treated for 1 hr with the indicated concentrations of NMDA (G) or were treated with 10 mM NMDA for the indicated periods of time (H). Results are means ± SEM of four experiments. mGluR1a truncation and that mGluR1a truncation requires prolonged activation of NMDA receptors.
mGluR1a Is Truncated by Calpain at Ser 936
We then determined which protease(s) mediated NMDAinduced mGluR1a truncation. Previous studies have indicated that both the calcium-dependent neutral protease calpain and caspases could be activated by neurotoxic concentrations of NMDA. Cortical neurons were pretreated with a calpain inhibitor, the cell-permeable calpain inhibitor III (10 mM), or the caspase inhibitor cpm-VAD-CHO for 2 hr followed by 50 mM NMDA for 1 hr. Pretreatment with calpain inhibitor III significantly blocked NMDAinduced truncation (Figure 2A ), while cpm-VAD-CHO had no effect. To confirm the activation of calpain by NMDA under our experimental conditions, we determined the levels of spectrin degradation fragments. The 145 kDa spectrin degradation band (spectrin DB), which is widely used as a marker of calpain activation, could not be detected under control conditions but appeared after treatment with NMDA ( Figure 2B ). In addition, NMDA-induced spectrin degradation could be blocked by ifenprodil (10 mM), a selective antagonist of NR2B subunit-containing NMDA receptors, but not by NVP-AAM077 (0.4 mM), a selective antagonist for NR2A subunit-containing NMDA receptors. Similarly, NMDA-induced mGluR1a truncation was selectively blocked by ifenprodil but not by NVP-AAM077. Note that under these conditions, the 120 kDa spectrin degradation fragment generated by caspase-induced spectrin truncation (Newcomb et al., 2000) was never observed, further strengthening the conclusion that calpain but not caspase was responsible for mGluR1a truncation.
The involvement of calpain in mGluR1a truncation did not necessarily imply that calpain could directly cleave the C terminus of mGluR1a. To confirm that mGluR1a truncation is directly mediated by calpain, we first transfected HEK293 cells with the N-terminal myc-epitopetagged mGluR1a. Two days later, mGluR1a was immunoprecipitated with anti-mGluR1a C-terminal antibody and incubated with different concentrations of m-calpain for (B) Calpain was activated by NMDA. Neurons were treated as indicated and total cell lysates were blotted with anti-spectrin or antimGluR1a 1142-1160 , respectively. Only the degradation bands of spectrin (spectrin DB, at $145 kD) are shown. NMDA-induced spectrin degradation and mGluR1a truncation were blocked by ifenprodil but not by NVP-AAM077. (C) Immunoprecipitated myc-mGluR1a was digested with m-calpain at the indicated concentrations (U/ml) for 30 min. The digested material was processed for SDS-PAGE and subjected to silver staining or immunoblots. With silver staining, myc-mGluR1a ($140 kDa) was cleaved by calpain into two bands of molecular weight 100 kDa (corresponding to the N-terminal fragment, as it was detected with the antimyc antibody) and 38 kDa (corresponding to the C-terminal fragment, as it was detected with anti-mGluR1a [1142] [1143] [1144] [1145] [1146] [1147] [1148] [1149] [1150] [1151] [1152] [1153] [1154] [1155] [1156] [1157] [1158] [1159] [1160] 
D.
(F) TAT-mGluR1 peptide blocked NMDA-induced mGluR1a truncation. Neurons were pretreated with the TAT-mGluR1 peptide or vehicle followed by NMDA, and total cell lysates were blotted with anti-mGluR1a 1142-1160 or anti-spectrin antibodies.
30 min. Aliquots of precipitated proteins were processed for SDS-PAGE and silver staining, and the rest of the samples were used for western blots with antibodies against the myc epitope or mGluR1a C terminus, respectively (Figure 2C) . With silver staining, the density of the 145 kDa band that represents full-length mGluR1a decreased dose dependently with calpain treatment. In parallel, two additional bands appeared after calpain treatment, with apparent molecular weights of 100 kDa and 38 kDa, respectively. The 100 kDa band proved to be the N terminus of mGluR1a derived from truncation, as it reacted with the anti-myc antibody. Likewise, the 38 kDa protein proved to be the C terminus of mGluR1a, as it was labeled with the anti-mGluR1a C-terminal antibody. These data indicated that calpain could directly cleave mGluR1a at the C terminus.
From . The GST fusion protein was expressed in and purified from BL21 Escherichia coli and digested with calpain. This fusion protein became about 2 kDa smaller after digestion, suggesting that the cleavage site was close to S
943
. To get enough C-terminal fragment for Edman protein sequencing, another construct was made by fusing the mGluR1a sequence from N 889 to L 1058 to the C terminus of GST. As expected, after digestion with calpain, this fusion protein generated a 10 kDa fragment. The N terminus of this fragment was sequenced to be YQGS with Edman degradation, indicating that the calpain cleavage site in mGluR1a is between S 936 and Y 937 ( Figure 2D ).
The molecular weight (MW) of mGluR1a from residues 1-936 is 104.87 kDa, which matches well with the apparent MW of the N-terminal fragment after truncation. The MW of mGluR1a residues 937-1199 is 28.41 kDa, which is lower than the 38 kDa apparent MW of the C-terminal fragment. However, the C-terminal domain of mGluR1a has a high percentage of proline (45 out of the 263 amino acids), with some proline-rich domains composed solely of prolines. Proline-rich proteins normally show higher apparent MW on SDS-PAGE, which might explain the seemingly different molecular weights of the C-terminal fragment. To obtain further confirmation of this truncation site, a stop codon was introduced into the myc-mGluR1a plasmid immediately after Ser 936 to generate a construct for truncated mGluR1a (myc-mGluR1aS 936 D). Transfected in HEK293 cells, this construct generated a protein with the same apparent molecular weight ($100 kDa) as the mGluR1a N-terminal fragment generated after calpain-mediated truncation ( Figure 2E ).
To selectively block calpain-mediated truncation of mGluR1a, a peptide was constructed by fusing the mGluR1a sequence spanning the calpain cleavage site with the TAT protein transduction domain, a procedure that has been used to transfer material across cell membranes (Wadia et al., 2004) . We reasoned that this peptide would compete with endogenous mGluR1a for calpain and therefore protect it from truncation. Incubation of brain membrane fractions with calpain resulted in truncation of both mGluR1a and spectrin. The TAT-mGluR1 fusion peptide dose dependently reduced calpain-mediated truncation of mGluR1a but not of spectrin. The TAT peptide itself showed no significant effect on calpainmediated truncation of mGluR1a or spectrin (see Supplemental Data available with this article online). We then tested the effect of the peptide on cultured neurons. Cortical cultures were incubated with different concentrations of TAT-mGluR1 for 90 min followed by 50 mM NMDA for 1 hr. As shown in Figure 2F , treatment with the peptide resulted in a dose-dependent inhibition of NMDA-induced mGluR1a truncation. At the lower concentrations (1-2 mM), the peptide significantly reduced mGluR1a truncation with little effect on spectrin degradation, while at higher concentrations (4-8 mM), spectrin degradation was also blocked.
C-Terminal Truncated mGluR1a Remains Functional
The main signaling mechanism activated by mGluR1a consists of PI hydrolysis through G protein and phospholipase C, which eventually leads to calcium release from internal calcium stores. Therefore, we first performed calcium imaging to determine whether mGluR1a remains functional following C-terminal truncation. Wild-type mGluR1 (myc-mGluR1a) or the truncated form (mycmGluR1aS 936 D) was cotransfected with DsRED (red fluorescent protein) into HEK293 cells. Two days after transfection, cells were loaded with a calcium reporter, Oregon green 488 BAPTA-1 AM (0.63% in extracellular solution). As shown in Figure 3 , a significant increase in intracellular calcium concentration could be detected after treatment of cells transfected with myc-mGluR1a with 100 mM DHPG, a selective agonist for group I mGluRs (maximum DF/F = 30.6 ± 4.2%; n = 8). This calcium response requires mGluR1a activation because no change in fluorescent signals could be observed in nontransfected cells. In cells transfected with myc-mGluR1aS 936 D, DHPG could induce qualitatively similar, although significantly smaller, calcium transients (maximum DF/F = 20.1 ± 2.1%; n = 10; p < 0.05, Student's t test for myc-mGluR1a versus myc-mGluR1aS 936 D). These data indicated that mGluR1a remains functional following C-terminal truncation at Ser 936 .
C-Terminal Truncation Alters mGluR1a Signaling
Activation of mGluR1a can also stimulate nonselective cation excitatory postsynaptic conductance. We therefore analyzed mGluR1a-dependent currents before and after calpain-mediated truncation. We transfected HEK293 cells with either myc-mGluR1a or myc-mGluR1aS 936 D plus GIRK1, GIRK2 or TRPC1. Application of DHPG evoked an inward current in HEK293 cells transfected with myc-mGluR1a and either TRPC1 or GIRK1, 2. Mean amplitude of DHPG-induced current in myc-mGluR1a/ TRPC1-transfected cells was À36.7 ± 9.6 pA (mean ± SEM, n = 7 cells), while in myc-mGluR1a/GIRK1, 2-transfected cells, average amplitude of whole-cell current was À24.2 ± 6.3 pA (n = 5 cells). In contrast, whole-cell currents were markedly reduced or absent in cells transfected with myc-mGluR1aS 936 D, with a mean amplitude of À9.7 ± 6.8 pA in myc-mGluR1aS 936 D/TRPC1-transfected cells (n = 5) and À1.4 ± 0.8 pA in myc-mGluR1-aS 936 D/GIRK1, 2-transfected cells (n = 3). As illustrated in Figure 4A , whole-cell response induced by wild-type mGluR1a was significantly greater than that mediated by truncated mGluR1a (p < 0.05, Student's t test for mycmGluR1a versus myc-mGluR1aS 936 D in both TRPC1-and GIRK1, 2-transfected cells).
As reported in previous studies, mGluR1 activation can stimulate the PI 3 K-Akt signaling pathway through the mGluRI-Homer-PIKE-PI 3 K signaling complex. Therefore, we tested whether this signaling mechanism remained functional after mGluR1a truncation. We first induced mGluR1a truncation by treating cortical neurons with 50 mM NMDA for 1 hr. Two hours after washing out NMDA, neurons were incubated with DHPG (50 mM) for 10 min. Neurons were then lysed and levels of Akt phosphorylation were determined with western blots by calculating the ratio of phosphorylated Akt to total Akt. DHPG induced a moderate increase in Akt phosphorylation levels in neurons (p < 0.05, n = 6, Student's t test for cont1 versus DHPG1) ( Figure 4B ). Pretreatment with NMDA reduced basal levels of phosphorylated Akt (p < 0.001, n = 6, Student's t test for cont1 versus cont2). Under this condition, DHPG failed to increase Akt phosphorylation levels (p = 0.27, n = 6, Student's t test for cont2 versus DHPG2). When neurons were pretreated with 8 mM TAT-mGluR1 for 90 min to block mGluR1a truncation, NMDA-induced reduction of Akt phosphorylation was partially reversed (p < 0.05, n = 6, Student's t test for cont3 versus cont2). More importantly, DHPG-induced increase of Akt phosphorylation was restored (p < 0.05, n = 6, Student's t test for cont3 versus DHPG3). Together, the data indicated that the mGluR1a-PI 3 K-Akt signaling pathway was disrupted by calpain-mediated mGluR1a truncation and that preventing truncation with the TATmGluR1 peptide restored this signaling mechanism.
C-Terminal Truncation Alters mGluR1a Targeting in Cortical Neurons
Previous studies have shown that the C-terminal domain of mGluR1a is crucial for its dendritic localization. Therefore, it was interesting to determine whether mGluR1a targeting was modified following calpain-mediated truncation. Cortical neurons were transfected with mycmGluR1a. After 48 hr, neurons were treated with 50 mM NMDA or vehicle for 1 hr. After 3 hr of washing out NMDA, neurons were fixed and stained with antibodies against the N-terminal myc epitope or the C terminus of mGluR1a, respectively. Full-length mGluR1a was selectively targeted to dendrites and almost excluded from axons ( Figure 5A ). But in $34% of neurons treated with NMDA (124 out of 367 neurons counted), myc immunoreactivity could be detected in axons, especially in the proximal segment, whereas immunoreactivity for the C terminus of mGluR1a was still restricted to dendrites ( Figure 5B ). These results indicated that NMDA-induced C-terminal truncation altered mGluR1a targeting.
To test whether NMDA-induced translocation of mGluR1a from dendrites to axons was an active process or passive diffusion after truncation, we transfected cortical neurons with myc-mGluR1aS 936 D. Targeting of mGluR1-aS 936 D 48 hr after transfection was dramatically different from that of full-length mGluR1a ( Figure 5C ). In the majority of transfected neurons ($73%, 500 out of 681 neurons counted), immunoreactivity for myc tag was strictly restricted to cell bodies ( Figure 5C , upper panel). The cellbody restriction was the same when immunostaining was performed 6 days after transfection, suggesting that it was not the result of a delay in expression or delivery but rather mediated by targeting signals. In a smaller fraction of neurons ($22%, 150 out of 681 neurons counted), mGluR1a was selectively targeted to axons ( Figure 5C , middle panel). There were also a few neurons ($4.5%, 31 out of 681 neurons counted) where immunostaining appeared in dendrites. However, in contrast to the even distribution of full-length mGluR1a in dendrites, truncated mGluR1a formed large clusters ( Figure 5C , bottom panel).
Distinct and Opposite Roles of Wild-Type and Truncated mGluR1a in Excitotoxicity
Calpain-mediated mGluR1a truncation was induced mainly by toxic concentrations of NMDA. The downstream signaling pathways of mGluR1a, including intracellular calcium release and activation of PI 3 K-Akt, are both important for excitotoxicity. Therefore, we postulated that NMDA-induced truncation would alter the role of mGluR1a in neuronal toxicity. To test this possibility, we first cotransfected neurons with green fluorescent protein (GFP) and a control vector, wild-type mGluR1a, or truncated mGluR1a. Two days later, neurons were treated with 25 mM glutamate for 1 hr. Twelve hours after treatment, neurons were stained with 0.5 mM ethidium homodimer 1 (EthD-1) for 10 min to label nuclei of dead cells. Numbers of GFP-expressing neurons and EthD-1-positive GFP-expressing neurons on each 18 3 18 mm coverslip were counted to calculate the percentage of dead cells. Toxic effects of glutamate treatment could readily be observed in most GFP-expressing neurons, which exhibited significant neurite retraction ( Figures 6A and 6B ). In neurons cotransfected with control vector, 35% (n = 9; an average of 405 GFP-expressing neurons were counted on each coverslip) of GFP-expressing neurons were positive for EthD-1 staining and therefore had died. In neurons cotransfected with wild-type mGluR1a, only 15% of neurons (n = 8; an average of 428 GFP-expressing neurons were counted on each coverslip) were EthD-1 positive, an effect that was statistically different from that in neurons cotransfected with control vector (p < 0.01, Student's t test). In contrast, 59% of neurons cotransfected with mGluR1aS 936 D (n = 9; an average of 439 GFP-expressing neurons were counted on each coverslip) were EthD-1 positive, an effect significantly higher than observed in neurons cotransfected with control vector (p < 0.05, Student's t test). The opposite effects of wild-type and truncated mGluR1a indicated that wild-type and truncated mGluR1a have distinct roles in excitotoxicity.
We then tested whether calpain-mediated truncation of endogenous mGluR1a also alters its role in excitotoxicity. We used NMDA to elicit mGluR1a truncation and evaluated the role of mGluR1 in neuronal toxicity by applying DHPG before and after truncation. Cortical neurons cultured on 18 3 18 mm coverslips were divided into six groups which received the following treatments: (1) control, vehicle; (2) NMDA, 100 mM NMDA for 1 hr; (3) DHPG before NMDA, DHPG, 100 mM for 1 hr, followed by 100 mM NMDA for 1 hr; (4) DHPG after NMDA, NMDA, 100 mM for 1 hr, followed by 100 mM DHPG for 1 hr; (5) DHPG + LY before NMDA, 100 mM DHPG was coapplied with 100 mM LY367385 for 1 hr followed by 100 mM NMDA for 1 hr; (6) DHPG + LY after NMDA, NMDA, 100 mM for 1 hr, followed by 100 mM DHPG coapplied with 100 mM LY367385. One day after treatment, all neurons were stained for 20 min with 0.5 mM EthD-1 to label dead cells and 2 mM calcein AM to label live cells. After washes, coverslips were mounted and one microscopy photo was immediately taken of the center area of each coverslip. EthD DHPG induced a moderate increase in Akt phosphorylation levels in neurons (p < 0.05, cont1 versus DHPG1, n = 6). Pretreatment with NMDA reduced levels of phosphorylated Akt (p < 0.001, cont1 versus cont2, n = 6) and abolished DHPG effect (p = 0.27, cont2 versus DHPG2, n = 6). Pretreatment with TAT-mGluR1 partially blocked NMDA-induced reduction in levels of phosphorylated Akt (p < 0.05, cont3 versus cont2, n = 6) and restored the effect of DHPG in activating Akt (p < 0.05, cont3 versus DHPG3, n = 6).
AM-positive cells) *100%. As shown in Figures 6C and 6D , control had 8% cell death (n = 12). In NMDA, cell-death rate increased to 37% (n = 12), which was significantly higher than that in control (p < 0.001, Student's t test), indicating toxicity of NMDA; 29% cell death was found in DHPG before NMDA (n = 9), which was significantly lower than that of NMDA (p < 0.001, Student's t test), suggesting a neuroprotective effect of DHPG under this condition. This effect was blocked by coapplying LY367385 (DHPG + LY before NMDA, 35.1% cell death, n = 11; p < 0.05 compared with DHPG before NMDA; p = 0.38 compared with NMDA, Student's t test), indicating that it was mediated by mGluR1. DHPG after NMDA had 54% cell death (n = 12), which was significantly higher than that of NMDA (p < 0.001, Student's t test), indicating a neurotoxic effect of DHPG treatment under this condition. This toxic effect was blocked by coapplying LY367385 (DHPG + LY after NMDA, 39.9% cell death, n = 9; p < 0.001 compared with DHPG after NMDA; p = 0.27 compared with NMDA, Student's t test). The opposite Neuron effects of DHPG before and after NMDA-induced truncation thus demonstrate the distinct roles of full-length and truncated endogenous mGluR1a. Based on these data, we reasoned that blockade of mGluR1a truncation might have neuroprotective effects. To test this possibility, cortical neurons were incubated with 2, 4, or 8 mM of TAT-mGluR1 peptide or vehicle for 90 min followed by 100 mM of NMDA for 1 hr. Neurons were stained with EthD-1 and calcein AM to determine the percentage of dead cells 24 hr after NMDA treatment. NMDA treatment significantly increased the proportion of dead cells (p < 0.001, n = 12-15, Student's t test, NMDA versus cont) ( Figures 6D and 6F) . Pretreatment with TAT-mGluR1 peptide dose dependently reduced NMDAinduced cell death (p < 0.001, n = 9-15, Student's t test for NMDA versus NMDA + TAT-mGluR1 8 mM, NMDA versus NMDA + TAT-mGluR1 4 mM, and NMDA versus NMDA + TAT-mGluR1 2 mM, respectively). The protective effect of TAT-mGluR1 was significant at a concentration as low as 2 mM, where the fusion peptide showed no significant effect on spectrin degradation. These data suggested that neuroprotection can be achieved by blocking mGluR1a truncation.
Truncation of mGluR1a Contributes to Excitotoxicity In Vivo
To test whether calpain-mediated truncation of mGluR1a occurs with excitotoxicity in vivo, we used kainic acidinduced seizure activity as a model, as neuronal damage resulting from seizures has been shown to be NMDA receptor dependent and calpain activation has also been well documented in this animal model (Siman and Noszek, 1988) . Two-month-old male SD rats received systemic injection of kainic acid (KA) (i.p., 12 mg/kg). Hippocampi were collected 3, 6, or 12 hr after injection, homogenized, and processed for immunoblots. As shown in Figure 7A , the 38 kDa C-terminal fragment of mGluR1a was detectable as early as 3 hr after KA injection. At 6 or 12 hr after injection, levels of full-length mGluR1a were significantly reduced. Similarly, the 145 kDa spectrin degradation band was present after KA injection, indicating that calpain was activated. A similar result was obtained in FVB/N mice 12 hr after subcutaneous injection of KA (30 mg/kg) ( Figure 7C ). Compared with that in cultured neurons, immunoreactivity of the mGluR1a C-terminal fragment after in vivo truncation was relatively weaker. The weaker immunoreactivity of the C-terminal fragment made it possible to determine the location of mGluR1a truncation in vivo with immunohistochemistry. Immunoreactivity for mGluR1a in stratum radiatum of hippocampus, especially in CA1, was significantly reduced following KA injection ( Figure 7B ). Interestingly, mGluR1a immunostaining in stratum oriens was not reduced or even slightly enhanced, suggesting that mGluR1a truncation might take place mainly in pyramidal cells and not in interneurons located in stratum oriens. GluR2/3 immunoreactivity was not significantly changed except in the CA3 pyramidal cell layer, where immunoreactivity largely disappeared. (A) SD rats were injected with kainic acid. Hippocampi were collected at the indicated times after injection and homogenates were blotted with anti-mGluR1a 1142-1160 and anti-spectrin. (B) FVB/N mice were injected with KA and brains were fixed 18 hr after injection. Brain sections were stained with antimGluR1a 1142-1160 and anti-GluR2/3. (C) TAT-mGluR1 blocked truncation of mGluR1a in vivo. FVB/N mice were injected with vehicle or TAT-mGluR1 at the indicated doses followed by KA injection. Hippocampi were collected 12 hr after KA injection and total homogenates were blotted with antimGluR1a 1142-1160 and anti-spectrin. (D) TAT-mGluR1 did not affect KA-induced seizures. FVB/N mice were injected (i.p.) with vehicle or TAT-mGluR1 followed by KA. Seizure activity was scored as described in Experimental Procedures. Results are presented as means ± SEM, n = 10-14. (E) Representative photos showing the neuroprotective effect of TAT-mGluR1 in vivo. Mice were first treated as described in (D). Seven days later, mice were sacrificed and brains were sectioned and processed for Nissl and silver staining.
To determine whether in vivo truncation of mGluR1a contributes to neuronal degeneration, we used the TATmGluR1 fusion peptide to block truncation. FVB/N mice were injected with different concentrations of TATmGluR1 fusion peptide (i.p., 25, 50, or 100 mg/kg) or vehicle 90 min before systemic KA injection (s.c., 30 mg/kg). mGluR1a truncation was significantly reduced following treatment with TAT-mGluR1 fusion peptide (50 and 100 mg/kg) ( Figure 7C ). As was observed in cultured neurons, KA-mediated spectrin degradation was also reduced by peptide treatment. To eliminate the possibility that blockade of calpain activation was due to an effect of the peptide on seizure susceptibility, we analyzed the effects of the fusion peptide on intensity and duration of KA-induced seizure activity. FVB/N mice were injected with 50 mg/kg TAT-mGluR1 peptide or vehicle followed by KA injection 90 min later. We did not observe any behavioral abnormality in mice that received TAT-mGluR1 peptide. Peptide pretreatment did not significantly alter KA-induced seizure (p > 0.05, n = 10-14, Student's t test for KA alone versus KA + TAT-mGluR1 for each hour, respectively) ( Figure 7D ). We then tested whether blockade of mGluR1a truncation could protect hippocampal neurons from KA-induced neurodegeneration. Because KA-induced neuron degeneration is closely related to seizure severity, only mice exhibiting stage 5 or higher seizures (see Experimental Procedures for a detailed description of the scale) were used for the cell toxicity experiment. Mice were perfused and fixed 7 days after KA injection. Brains were sectioned and processed for Nissl and silver staining. Representative photos from KA alone or peptide-pretreated (50 mg/kg) mice are shown in Figure 7E . As previously reported in this mouse strain (Schauwecker and Steward, 1997) , KA induced severe neurodegeneration in CA1 and CA3, as illustrated by the reduction of Nissl staining and appearance of degenerated neurons in silver staining (degenerated neurons were stained black). Pretreatment with the TAT-mGluR1 peptide significantly reduced KA-induced neurodegeneration, especially in CA1. Among the eight mice injected with KA and vehicle, five exhibited severe neurodegeneration in CA1 and CA3, two mice exhibited moderate neurodegeneration, and only one mouse appeared relatively normal. In contrast, among the eight mice pretreated with TAT-mGluR1 peptide, only two showed moderate neurodegeneration, one showed a low level of neurodegeneration, while the remaining five appeared normal (see Supplemental Data). Together, the data indicate that blockade of mGluR1a truncation in vivo protects neurons from KA-induced degeneration.
DISCUSSION
Altered Signaling and Targeting of mGluR1a by Calpain-Mediated Truncation
Calpain is a family of calcium-activated cysteine proteases. m-calpain and m-calpain are the two calpain isoforms ubiquitously distributed in mammalian cells. Calpain normally induces limited cleavage of substrate proteins to modify rather than abolish their functions (reviewed by Goll et al., 2003) . In the central nervous system, calpain is important for neural development, synaptic plasticity, and neural degeneration. Our laboratory previously demonstrated calpain-mediated truncation of both AMPA (Bi et al., 1996) and NMDA receptors (Bi et al., 1998) . The present study demonstrates that calpain also truncates the Cterminal domain of mGluR1a.
The mGluR1a signaling mechanism involves the Gq family of heterotrimeric G proteins. The major signal transduction mechanism for mGluR1 consists of activation of phospholipase C (PLC), which hydrolyzes membrane phosphoinositides and leads to IP 3 -mediated Ca 2+ release from intracellular stores (Masu et al., 1991) . The mGluR1a-G protein coupling involves mainly the second intracellular loop of the receptor (Gomeza et al., 1996) ; therefore, it is not surprising that mGluR1a remains functional after calpain-mediated truncation, which removes a long fragment from the intracellular C-terminal domain. Besides interacting with G proteins, mGluR1a also directly interacts via its large intracellular C-terminal domain with several other proteins, including Homer family proteins (Fagni et al., 2002) , calmodulin and Siah1A (Ishikawa et al., 1999) , and membrane channels (Saugstad et al., 1996; Kitano et al., 2003; Kim et al., 2003) . The Homer binding motif is located in the distal C terminus of mGluR1a and downstream of the calpain cleavage site. The binding of the receptor to Homer proteins is essential for coupling mGluR1a with the PI 3 K-Akt system (Rong et al., 2003) . Homer proteins also serve as a bridge linking mGluR1a in cell plasma membranes with IP 3 receptors in the endoplasmic reticulum membrane and facilitate mGluR-dependent calcium release from intracellular stores (Fagni et al., 2002) . As expected, mGluR1-PI 3 KAkt signaling was disrupted by calpain-mediated truncation. The mGluR1a-induced calcium transient was also moderately reduced. mGluR1a also gates some membrane channels, such as TRPC1 (Kim et al., 2003) and GIRK1, 2 (Saugstad et al., 1996) , which transduce mGluR1a-dependent excitatory postsynaptic current. The detailed mechanism responsible for mGluR1a/membrane channel interactions is largely unknown, and our data indicated that the C-terminal sequence located downstream of the calpain cleavage site is critical for those interactions.
Using immunogold electromicroscopy, Lujan et al. (1996) located mGluR1a to the perisynaptic area of postsynaptic sites. Consistent with this finding, mGluR1a was found to be selectively targeted to dendrites in cultured neurons (Stowell and Craig, 1999) . A detailed analysis of mGluR1a targeting revealed two distinct targeting signals in the C-terminal domain, RRK 877-879 for axonal targeting and another one located in more distal sequences. It has been suggested that the axonal targeting signal is masked by the proximal C terminus (residues 1012-1071) of mGluR1a, resulting in selective delivery of mGluR1a to dendrites (Francesconi and Duvoisin, 2002 Potential Roles of NMDA Receptor/mGluR1 Interactions in Excitotoxicity NMDA receptors and mGluR1 are colocalized on the postsynaptic membrane and coactivated by glutamate release from presynaptic sites. Functional interactions between these two types of receptors have long been noted (Lan et al., 2001) . Physical interactions between the two receptors have also been proposed. It was suggested that mGluR1 could be linked to NMDA receptors through the Homer-Shank-PSD95 complex (Tu et al., 1999) or by Ephrin (Calo et al., 2005) . These physical interactions would keep mGluR1 close to NMDA receptor channels and target it for cleavage by locally activated calpain.
Interactions between NMDA and mGluR1 receptors in excitotoxicity appear complicated. Activation of mGluR1 was reported to attenuate NMDA-induced neurotoxicity in cortical neuronal cultures (Koh et al., 1991) and in organotypic hippocampal slice cultures (Baskys et al., 2005) . Similarly, pretreatment with mGluRI agonists reduced the excitotoxic effects induced in the retina by intraocular NMDA injection (Siliprandi et al., 1992) . However, many studies have indicated that mGluR1 activation exacerbates NMDA receptor-mediated neurotoxicity (Calo et al., 2005; Bruno et al., 1995) . Interestingly, activation of mGluR1 before NMDA application tends to be neuroprotective (Blaabjerg et al., 2003) , whereas activation of mGluR1 after NMDA application tends to enhance NMDA toxicity (Bruno et al., 1995) . Similarly, the protective effects of mGluRI agonists in ischemia are time dependent: they are neuroprotective only when administered before the onset of ischemia (Schroder et al., 1999) .
Our findings regarding NMDA-induced mGluR1a truncation provide a possible explanation for these phenomena: before NMDA application or onset of ischemia, mGluR1a receptors are coupled to PI 3 K-Akt signaling and their activation is neuroprotective. Although mGluR1a activation leads to calcium release from internal stores, the extent of calcium release might be too low and transient to produce significant toxic effects. Following NMDA application or onset of ischemia, NMDA receptor activation induces calpain-mediated truncation of mGluR1a. As a result, the neuroprotective effect of the mGluR1a-PI 3 K-Akt signaling cascade would be disrupted. In addition, mGluR1a-dependent calcium release from intracellular stores would further contribute to calcium overload due to calcium influx through NMDA receptors and thus enhance neurotoxicity. Finally, because mGluR1 also exhibits presynaptic localization and function (Herrero et al., 1998; Moroni et al., 1998) , truncationmediated mGluR1a translocation to axons might further enhance glutamate release, thereby exacerbating excitotoxicity. Together, NMDA receptor activation followed by calpain-mediated truncation of mGluR1a constitutes a positive feedback loop for excitotoxicity.
Accumulating evidence suggests that calpain also plays a critical role in excitotoxicity. Overactivation of NMDA receptors leads to calpain activation, and calpain blockade protects neurons from excitotoxicity (Higuchi et al., 2005) . By cleaving different substrates, calpain triggers multiple neurotoxicity mechanisms. First, by partial truncation of NMDA receptors (Simpkins et al., 2003) and the Na + /Ca exchanger (Bano et al., 2005) , calpain enhances calcium overload. Second, through degradation of intracellular antiapoptotic proteins, such as NF-kB (Scholzke et al., 2003) , calpain promotes cell-death signaling. Third, by degrading cytoskeleton proteins such as spectrin, calpain disrupts cell structure. In the current study, we show that calpain-mediated mGluR1a truncation plays a critical role in excitotoxicity by both disrupting neuroprotective signaling and enhancing neurotoxic signaling. In the future it will be interesting to test the involvement of this positive feedback loop, namely NMDA receptor/calpain activation/mGluR1a truncation in other models of neurodegeneration where excitotoxicity has been implicated, such as ischemia, Parkinson's disease, and Alzheimer's disease. Moreover, further optimization of the TAT-mGluR1 peptide might provide a very useful tool not only to test this mechanism in these diseases but also to develop new therapeutic treatments.
EXPERIMENTAL PROCEDURES
Materials
Monoclonal anti-mGluR1a 1142-1160 antibody (610965) was obtained from BD Pharmingen (San Diego, CA, USA), anti-myc (ab32) was from Abcam (Cambridge, MA, USA), anti-mGluR5 (06-451) was from Upstate (Charlottesville, VA, USA), anti-VGluT1 (135 302) was from Synaptic Systems (Goettingen, Germany), anti-spectrin (1622) and anti-GluR2/3 (1506) were from Chemicon (Temecula, CA, USA), and anti-phospho-Akt (S473) (AF887) and total Akt (MAB2055) were from R&D Systems (Minneapolis, MN, USA). Human m-calpain was obtained from Sigma (C6108; St. Louis, MO, USA), calpain inhibitor III (208722) and cpm-VAD-CHO (218830) were from Calbiochem (San Diego, CA, USA), APV, CNQX, DHPG, LY367385, and MPEP were from Tocris (Ellisville, MO, USA), and NVP-AAM077 was a gift from Dr. Yves P. Auberson. TAT peptide was obtained from Anaspec (San Jose, CA, USA). TAT-mGluR1 peptide was synthesized by USC/Norris Comprehensive Cancer Center Core Facilities. The myc-mGluR1a construct was obtained from Dr. Anna Francesconi. GST-mGluR1a fusion proteins were made by subcloning mGluR1a sequences Neurons were switched to maintenance medium (neurobasal medium supplemented with B27 and 0.5 mM glutamine) the next day and fed twice per week until ready for experiments at 14-18 DIV. Neurons were transfected with a modified calcium phosphate precipitation method (Jiang et al., 2004) . HEK293 cells were transfected with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
SDS-PAGE and Immunoblotting
Cultured cells or brain tissues were homogenized in boiling lysis buffer (1% SDS, 10 mM Tris, 0.2 mM sodium ortho-vanadate [pH 7.4]). The lysate was denatured at 95 C for 5-10 min, sonicated, and centrifuged at 14,000 rpm for 30 min. Supernatants containing equal amounts of total proteins were processed for SDS-PAGE and immunoblotted with standard chemiluminescence protocols. Blots were digitized and quantified with NIH image software. All band intensities were normalized to that of control samples. For immunoprecipitation, cells were lysed with modified radioimmunoprecipitation buffer and lysates were incubated with anti-myc or anti-mGluR1a 1142-1160 antibodies. Proteins were pulled down with protein A agarose. Silver staining of SDS gels was conducted with the European Molecular Biology Laboratory silver staining protocol.
Immunocytochemistry, Immunohistochemistry, and Silver Staining For immunocytochemistry, neurons were fixed with 4% formaldehyde in PBS (room temperature, 10 min) and permeabilized with 1% Triton X-100 for 5 min. After blocking with 5% goat serum (60 min), neurons were incubated with primary antibodies dissolved in 0.5% goat serum in PBS for 1 hr. Neurons were then incubated with a corresponding fluorescence-tagged secondary antibody for 30 min. For immunohistochemistry, mice were deeply anesthetized with ketamine and xylazine and intracardially perfused with 20 ml chilled PBS (pH 7.4) followed by 100 ml 4% formaldehyde. Brains were removed and postfixed for 2 hr at room temperature. After incubating in PBS with 30% sucrose until sinking, brains were cut into 30 mm thick sections on a cryostat. Free-floating brain sections were immunostained with a VECTASTAIN ABC (standard) kit from Vector Laboratories (Burlingame, CA, USA). Brain-section silver staining was conducted with FD NeuroSilver kit I from FD NeuroTechnologies (Ellicott City, MD, USA) with the manufacturer-provided protocol.
Electrophysiological Recordings HEK293 cells plated on poly-D-lysine-coated coverslips were transfected with mGluR1a (either wild-type or truncated form) + TRPC1 + red fluorescent protein (DsRED), or DsRED alone, using lipofectamine (Lipofectamine 2000; Invitrogen). For each well of a 24-well plate, 0.5 mg lipofectamine and cDNAs (0.4 mg mGluR1a + 0.4 mg TRPC1 + 0.1 mg DsRED; DsRED alone, 0.1 mg) were used for transfection. Electrophysiological recording was conducted 48 hr after transfection. In some experiments, TRPC1 was replaced with G protein-coupled inwardly rectifying potassium channel cDNAs (GIRK1 and GIRK2, 0.4 mg each). HEK293 cells on coverslips were transferred to a recording chamber continuously perfused with extracellular solution (ECS) (pH 7.4) containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 1.3 mM CaCl 2 , 25 mM HEPES, and 33 mM glucose. Transfected cells were identified from their DsRED signal under a fluorescence upright microscope. Patch pipettes were pulled from borosilicate glass capillaries (Sutter Instrument Company, Novato, CA, USA) and filled with an intracellular solution (pH 7.2) (300-310 mOsm) composed of 115 mM Cs gluconate, 17.5 mM CsCl, 10 mM HEPES, 2 mM MgCl 2 , 10 mM EGTA, 4 mM ATP, and 0.1 mM GTP. For GIRK current recordings, the Cs in the intracellular solution was replaced with K + .
Recordings of whole-cell currents were obtained following application of DHPG (100 mM) using a fast perfusion system. An Axopatch 200B amplifier (Axon Instruments, Union City, CA, USA) was used for recording. Access resistance was monitored throughout each experiment. Recordings with a series resistance variation of more than 10% were rejected. No electronic compensation for series resistance was used. Whole-cell current recordings were performed in voltage-clamp mode and the membrane potential was maintained at À60 mV. Recorded currents were blocked by the mGluR1 antagonist LY367345 (50 mM; Sigma) (data not shown). Recordings were low-pass filtered at 2 kHz, sampled at 10 kHz, and stored on a PC using Clampex 8.2 (Axon).
Calcium Imaging HEK293 cells plated on poly-D-lysine-coated 16 mm coverslips were transfected with mGluR1a (either wild-type or truncated form) + DsRED. Two days after transfection, cells were incubated with a calcium reporter Oregon green 488 BAPTA-1 AM (0.63% in ECS) for 30 min. After washes with ECS, intracellular calcium concentration changes in Oregon green-loaded cells were monitored with a cool CCD camera mounted on a microscope under a 633 objective with the help of Openlab 3.7.5 software (Improvision, Coventry, UK) running on a PowerMac computer. Although all HEK cells were loaded with Oregon green, only 10%-20% of them were mGluR1 transfected so that nontransfected HEK cells in the same visual field could be used as controls. To induce mGluR1-dependent intracellular calcium release, cells were perfused with an extracellular solution containing 100 mM DHPG for 15 s. Images were acquired continuously before and after DHPG application at 5 Hz for 30 s and analyzed offline using Image J software (National Institutes of Health).
Cell Toxicity Assay
Cell live/dead condition of cultured neurons was assessed with the LIVE/DEAD Viability/Cytotoxicity kit (L-3224; Invitrogen). In this kit, EthD-1 (ethidium homodimer 1, red fluorescent when binding to DNA) is used to stain the nucleus of dead cells with disrupted cell membrane integrity; calcein AM (green fluorescent once it is converted by the esterase of live cells) is used to stain live cells. Cultured cortical neurons were incubated with 0.5 mM EthD-1 and/or 2 mM calcein AM (diluted with neurobasal culture medium) for 10-20 min and washed with neurobasal medium twice before observation under the microscope.
Behavioral Assessment of KA-Induced Seizure Activity Seizure activity was assessed with methods described by Holcik et al. (2000) with some modifications. Mice were assigned a score every 5 min after KA injection according to a seven-stage scale: 0 represents normal behavior; 1, immobility; 2, rigid posture; 3, repetitive scratching, circling, or head bobbing; 4, forelimb clonus, rearing, and falling; 5, repeated episodes of level 4 behaviors; 6, severe tonic-clonic behavior; and 7, death. The 12 scores obtained each hour following KA injection were summed to generate the seizure score for that hour.
All animal experiments were conducted in accordance with NIH guidelines and protocols approved by the Institutional Animal Care and Use Committee with care to minimize distress to the animals.
Supplemental Data
Supplemental Data include the effects of mGluR1a point mutations on calpain-mediated truncation and of TAT-mGluR1 peptide on calpainmediated truncation of mGluR1a in brain membrane fractions and on kainic acid-induced neurodegeneration, and can be found with this article online at http://www.neuron.org/cgi/content/full/53/3/399/ DC1/.
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